Log In
BCIQ
Print this Print this
 

TRC253 (formerly JNJ-63576253)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionSmall molecule high affinity competitive inhibitor of wild type androgen receptor and multiple androgen receptor mutations
Molecular Target Androgen receptor
Mechanism of ActionAndrogen receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation
PartnerTracon Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$155.0M

0

$105.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/28/2016

$155.0M

0

$105.0M

Get a free BioCentury trial today